Milestone Pharmaceuticals Inc.
MISTNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MIST. That does not mean none is planned.
Get an email about MIST's next catalysts
Track Milestone Pharmaceuticals (MIST) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
MIST Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.20 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Etripamil NS | Phase 3 | Tachycardia, Supraventricular | - | - |
Frequently asked questions
What is in Milestone Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Milestone Pharmaceuticals Inc.'s (MIST) pipeline across Phase 3. Its lead program is Etripamil NS (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Milestone Pharmaceuticals Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Milestone Pharmaceuticals Inc. (MIST) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MIST biotech catalysts?→
Add MIST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Milestone Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.